Mesoblast Limited (NASDAQ:MESO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The brokerage currently has a $6.50 target price on the stock. Zacks Investment Research‘s price target indicates a potential upside of 0.78% from the stock’s previous close.

According to Zacks, “Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. “

MESO has been the subject of several other reports. Cantor Fitzgerald reissued a “buy” rating on shares of Mesoblast Limited in a report on Wednesday, August 23rd. Maxim Group set a $14.00 price objective on Mesoblast Limited and gave the company a “buy” rating in a report on Wednesday, August 30th. BidaskClub lowered Mesoblast Limited from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. Credit Suisse Group set a $11.00 price objective on Mesoblast Limited and gave the company a “hold” rating in a report on Tuesday, July 18th. Finally, ValuEngine lowered Mesoblast Limited from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $13.14.

Shares of Mesoblast Limited (NASDAQ MESO) opened at 6.45 on Wednesday. Mesoblast Limited has a 12-month low of $4.01 and a 12-month high of $12.50. The company’s 50-day moving average price is $6.01 and its 200 day moving average price is $8.05. The firm’s market capitalization is $547.89 million.

TRADEMARK VIOLATION WARNING: This story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/10/06/mesoblast-limited-meso-rating-increased-to-buy-at-zacks-investment-research.html.

About Mesoblast Limited

Analyst Recommendations for Mesoblast Limited (NASDAQ:MESO)

Receive News & Stock Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related stocks with our FREE daily email newsletter.